Inclusion Criteria:

          -  1. Diagnosis of recurrent T-cell acute lymphoblastic leukemia (T-ALL), T-cell acute
             lymphoblastic lymphoma (T-LLy), or T-non-Hodgkin lymphoma (T-NHL, including
             Angioimmunoblastic T-cell lymphoma (AITL), Enteropathy-associated T-cell lymphoma
             (EATL), Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), Peripheral
             T-cell lymphoma (PTCL) NOS, Anaplastic large cell lymphoma (ALCL), Adult T-cell
             leukemia/lymphoma, T cell prolymphocytic leukemia with symptomatic disease, Extranodal
             NK/T cell lymphoma, Mycosis fungoides/ Sezary Syndrome Stage IIB or higher))

             2. CD7-positive tumor (≥20% CD7 positive blasts by flow cytometry or
             immunohistochemistry (tissue)）

             3. Hgb ≥ 7.0 (can be transfused)

             4. Life expectancy greater than 12 weeks

             5. Informed consent explained to, understood by and signed by the patient/guardian.
             Patient/guardian is given a copy of informed consent.

        Exclusion Criteria:

          1. Pregnant or lactating.

          2. Tumor in a location where enlargement could cause airway obstruction (per investigator
             discretion).

          3. Active infection with HIV or HTLV.

          4. Clinically significant viral infection or uncontrolled viral reactivation of
             EBV(Epstein-Barr virus), CMV(cytomegalovirus), ADV(adenovirus), BK-virus, or HHV(human
             herpesvirus)-6.

          5. Any of the following cardiac criteria: Atrial fibrillation/flutter; Myocardial
             infarction within the last 12 months; Prolonged QT syndrome or secondary prolonged QT,
             per investigator discretion. Cardiac echocardiography with LVSF (left ventricular
             shortening fraction)<30% or LVEF(left ventricular ejection fraction)<50%; or
             clinically significant pericardial effusion. Cardiac dysfunction NYHA(New York Heart
             Association) III or IV (Confirmation of absence of these conditions on echocardiogram
             within 12 months of treatment).

          6. CNS abnormalities: Presence of CNS(central nervous system)-3 disease defined as
             detectable cerebrospinal blast cells in a sample of CSF(cerebrospinal fluid) with ≥ 5
             WBC( white blood cell)s per mm3 (unless negative by the Steinherz/Bleyer algorithm);
             Presence of any CNS disorder such as an uncontrolled seizure disorder, cerebrovascular
             ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS
             involvement.